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Abstract
Asthma is a chronic heterogeneous illness of the lower airway with an inflammatory basis, developing from hyperresponsive-
ness and bronchial obstruction. One of the more unfavourable processes occurring in the airway are the long-term changes of 
the respiratory tract known as remodelling, resulting in complete irreversible obstruction. Bone morphogenetic protein (BMP) is 
a member of the Transforming Growth Factor beta (TGF-b) superfamily, which regulates processes in embryonic and post-em-
bryonic development. The role played by BMP is regulation of degradation and remodelling of the extracellular matrix, which 
is one of the elements involved in the reconstruction of the structure of the bronchi in severe asthma. This paper presents the 
antagonistic properties of BMP against TGF-b, anti-inflammatory and counteracting fibrosis in the respiratory tract. The current 
state of knowledge indicates that this group of cytokines are potential new markers of remodelling in severe asthma, and further 
studies on their therapeutic value are necessary.
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Introduction
Asthma is a heterogeneous, chronic inflam-
matory disease typified by airway hyperrespon-
siveness and paroxysmal variable bronchial 
obstruction provoked by specific and non-specific 
factors [1]. The pathophysiological basis of asth-
ma stems from three phenomena: airway hyperre-
sponsiveness to specific and non-specific factors, 
variable and reversible airway obturation, and 
chronic inflammation of the bronchial mucosa. 
The inflammation process involves inflam-
matory cells such as Antigen Presenting Cells 
(APC), T lymphocytes, mast cells, eosinophils, 
macrophages and neutrophils, as well as struc-
tural cells including epithelial cells, myocytes, 
fibroblasts and myofibroblasts, nerve cells and 
vascular endothelial cells [2]. One of the causes of 
airway hyperresponsiveness is epithelial damage 
[3]. The CysLT1 receptor is activated with C4, 
D4 and E4 leukotrienes, secreted by mast cells, 
and this is followed by muscle spasms. Besides 
leukotrienes, mast cells also secrete a number 
of pro-inflammatory cytokines, prostaglandins 
and histamine, particularly following repetitive 
stimulation by allergens. Following the onset of 
the disease, the bronchial walls of the respiratory 
tract undergo an ongoing, highly-adverse process 
known as remodelling, which results in reduced 
elasticity, thickening of the muscular layer, in-
creased angiogenesis and the deposition of an 
extracellular matrix (ECM) [4]. The activation of 
fibroblasts, and the differentiation and secretion 
of increased amounts of collagen is caused mainly 
by TGF-b1. 
Type-b transforming growth factors (TGF-b) 
are pleiotropic compounds produced by most 
epithelial and fibroblastic cells. They share the 
Advances in Respiratory Medicine 2017, vol. 85, no. 2, pages 109–115 
110 www.journals.viamedica.pl
action of cytokines, as well as of stimulators and 
inhibitors of growth and proliferation [5, 6]. The 
subfamily of the TGF-b superfamily includes 
Bone Morphogenetic Proteins (BMP), Growth 
Differentiation Factors (GDF) and Anti-Müllerian 
Hormone (AMH) [7]. 
Bone morphogenetic proteins regulate a num-
ber of developmental processes for both embryonic 
and post-embryonic organogenesis: they take part 
in bone formation, wound healing and immune 
response [8, 9]. BMP expression was first discov-
ered in bones, but has also been found in other 
organs such as the bone primordia (BMP-2,4,5,7), 
kidneys (BMP-3,4,7), heart (BMP-2,4,6,7) and 
teeth (BMP-3,4,7). In addition, BMP subtypes 3, 4 
and 7 have been observed in lung tissue [10–13]. 
Among the 20 known members of the BMP fam-
ily, the strongest osteoinductive properties are 
demonstrated by isoforms BMP-2, 6 and 9, both 
in the bone tissue and heterotopic areas [14]. 
However, although BMP-3, 4 and 7 have less oste-
oinductive potential, they demonstrate regulatory 
activity in the development and differentiation of 
fibroblasts, which may take part in the remodel-
ling of the respiratory tract [15, 16]. 
The BMP-SMAD signalling pathway
Cellular transduction of signalling by BMP 
occurs through the SMAD protein (mothers 
against decapentaplegic homolog), in a similar 
way to proteins from the TGF-b family. Two types 
of BMP receptors are required to carry the signal: 
the serine-threonine kinases BMPR-I and BMPR-II 
(BMPR- bone morphogenetic protein receptor). 
BMPR-I comprises two receptor subtypes, BM-
PR-1A (ALK-3) and BMPR-1B (ALK-6), and activin 
receptor-like kinase-2 (ALK-2), binding activin 
and BMP-7, while BMPR-II includes BMPR-2, 
a  type II activin receptor (ActRII) and type IIB 
activin receptor (ActRIIB) [17]. The signal can 
be passed into the cell nucleus via the canonical 
pathway (with the participation of SMAD), or 
a non-canonical pathway by MAP kinases (MAPK- 
mitogen activated protein kinases), N-terminal 
kinase (JNK), p38 kinase or Phosphoinositi-
de-3-kinase (PIK3), RAS proteins. 
The SMAD family of mediating proteins are 
derived from two homologous proteins: Sma, 
occurring in Caenorhabditis elegans, and Mad, 
present in Drosophila melanogaster. The SMAD 
family can be divided into three groups: pro-
teins activated by the R-SMAD receptor, such as 
SMAD-1,2,3,5 or 8; Co-SMAD, i.e. co-mediating 
protein SMAD4 ; and the I-SMAD inhibitory 
proteins, represented by SMAD 6 and 7. SMAD 
1, 5 and 8 are activated by BMP signalling. In 
canonical signalling, after merging, the complex 
formed by BMP and SMAD-1, 5 or 8 links to the 
common mediator Co-SMAD4, which allows 
transport to the cell nucleus [18]. In the cell nu-
cleus, the R-SMAD/Co-SMAD complex binds to 
the promotors associated with the SRE sequence 
(SMAD-Response Elements) and following that 
binding, it regulates their transcription [19]. 
The genes responsible for mediating SMAD 
with BMP depend on the type of cell or tissue 
[20]. SMAD acts as a mediator in inflammation 
and fibrosis, as well as in epithelial-to-mesen-
chymal transition (EMT) induced by TGF-b1 [21]. 
BMP-6 and BMP-7 activate only two of the three 
R-SMADs , i.e. SMAD1 and SMAD5, whereas 
BMP-2 activates all SMAD subtypes [22]. It is 
suggested that some proteins from the BMP family 
are able to deactivate parts of the SMAD1 and 
SMAD5 regulatory proteins [23]. BMPs, together 
with their BMPR-SMAD signal pathway, TGF-b 
and TGFbR-SMAD undergo mutual interactions. 
The co-mediating protein Co-SMAD 4 is the 
common link. When the intracellular level of 
SMAD4 is limited, ligands of the TGFbR and 
BMPR receptors modulate its competing activity 
towards SMAD4 [24]. Correct BMP signalling is 
essential for the correct promotion and regulation 
of regeneration, repair and maintenance of tissues 
where BMP expression is found.
Due to the fact that BMPs belong to the TGF-b 
superfamily, they have similar signal transduc-
tion mechanisms and common co-mediating 
protein and the confirmed expression of certain 
subtypes of BMP in the respiratory tract, which 
results in the need for further studies concern-
ing the possible role of BMPs in the pathological 
mechanism of bronchial asthma development 
and subsequent remodelling. Besides, BMPs may 
be hypothetically used as biomarkers of disease 
progress in patients.
The BMP protein and BMPR receptor: expression, 
function and role in the respiratory tract
Although BMP-3 remains not fully under-
stood, the BMP-3 gene is known to be present in 
chromosome 4q21.21 [26]. The BMP-3 molecule 
demonstrates high affinity to the activin receptor 
ActRII, but lower to ActRIIb. Next, the signal 
is carried to the cell nucleus using the SMAD 
protein [27]. Expression is located mainly in the 
neuroectodermis and the forming s periosteum, 
which suggests that BMP-3 may be engaged in 
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Figure 1. BMP signalling pathways based on [25], own modified. In canonical pathway of BMP signal is transduced through the heteromeric 
complex with BMP ligand and type I and type II BMP receptors. That complex after phosphorylation is binded with phosporylated SMAD 1, 5, 8 
and then merged with co-mediating protein SMAD4, then this newly-formed complex is transported into the nucleus for initiating the transcription. 
In the non-canonical pathway signal may be transduced via MAPK1, PIK3, MAPK8, RAS. There are also several extracellular inhibitors for BMP, i.e. 
NOG, CHRD (chordin), GREM1 (Gremlin) and FST (follistatin) or by the receptor BAMBI
the early development of bones during embryo-
genesis [26]. Studies of six-week-old embryos 
have revealed the expression of BMP-3 mRNA in 
epithelial stem cells of the bronchial epithelium, 
and later in epithelial cells lining the buds of 
bronchial branches [11]. Some studies propose 
that BMP-3 may act as an inhibitor for other 
members of the BMP family. This hypothesis has 
been confirmed by tests on double knockout mice 
in which a significant increase in bone mass was 
observed; however, more frequent spontaneous 
fractures were observed in the case of mice with 
BMP-3 overexpression [28]. In a study of allergic 
rhinitis in a mouse model, a significant reduction 
in the expression of BMP-3 and BMP-5 was ob-
served following exposure to the allergen Asper-
gillus fumigatus. In the same test, the expression 
of a  range of cytokines from Fibroblast Growth 
Factors (FGF) and Matrix Metalloproteinases 
(MMP) was found to be elevated after exposure 
to a specific allergen. These findings suggest that 
signal transduction in cells intended for initiating 
the process of fibrogenesis and remodelling is 
initiated earlier in inflammatory illnesses [29].
BMP-4 is an important regulatory molecule, 
inducing mesoderm formation and tooth and limb 
growth during embryogenesis, and the later for-
mation of bone tissue and healing of fractures [17]. 
The gene for BMP-4, mapped onto chromosome 
14q-22.2, has two promotor regions, which are 
subject to expression occurring in a cell type-spe-
cific manner. It is important to note that construc-
tion of BMP-4 includes the propeptide TGF-b1 
domain and the TGF-b domain to form an active 
dimer [30]. BMP-4 is an important signalling 
molecule for lung embryogenesis [13], with the 
epithelium of the distal tips of the terminal buds 
demonstrating greater BMP-4 mRNA expression 
than the adjoining mesenchyme. Tests on trans-
genic mice have revealed that BMP-4 misexpres-
sion, controlled by the enhancer sequences of 
the Surfactant Protein C (SP-C) promotor, leads 
to a reduction in lung size, hyperinflation of the 
bronchiole tips and impaired gas exchange after 
birth [15]. It has been postulated that BMP-4 may 
play a  role in the local inhibition of bronchial 
epithelial cell proliferation, which would inhibit 
the signal modulating FGFs. This theory has been 
demonstrated by the presence of hypoplastic epi-
thelial tissue production in studies of transgenic 
mice with BMP-4 misexpression, and in studies 
where the BMP-4 ligand was added to in vitro 
epithelial cultures lacking BMP-4 expression [31]. 
Jefferey et al. [32] also note that BMP-4 has 
an inhibitory effect on fibrogenesis. It was found 
that BMP-4 has both antiproliferative and pro- 
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-differentiation effects on the lung epithelium. 
After examining the BMP-4 signalling pathway, 
using both the SMAD and mitogen-activated pro-
tein kinase (MAPK) pathways, it can be suggested 
that while the promotion of proliferation is depen-
dent on the action of SMAD1 and c-Jun N-termi-
nal kinase (JNK), the antiproliferative properties 
are dependent on SMAD1. As SMAD1 is the 
predominant signalling molecule engaged in the 
proliferation and differentiation of fibroblasts, it 
may inhibit the processes using BMP-4. Although 
the role of BMP-4 in the degradation of the ECM 
is not fully understood, BMP-4 is believed to be 
able to counter its growth and induce the prolif-
eration of normal human lung fibroblasts (NHLF) 
using TGF-b1 [33]. Most importantly, studies 
which have been recently conducted reveal that 
BMP-4 not only regulates the level of MMP-13 
expression connected with fibroblasts, but also 
the expression of MMP-13 induced by TGF-b1 
[16, 34]. However, although these studies do not 
confirm that BMP-4 has a direct influence on fi-
broblast proliferation, they do indicate that it has 
an indirect action, which encourages the search 
for new diagnostic and therapeutic applications. 
The possibility of the partial reversal or inhibition 
of remodelling translates into improvements in 
the quality of life of patients and prevents some 
of the effects of severe asthma.
BMP-7, also known as osteogenic protein 1 
(OP1), is mapped on chromosome 20q13.31. BMP-
7 is expressed in the limb buds, heart, the retinal 
neuroepithelium, the lens and cornea, kidney and 
lung fibroblasts [35]. BMP-7 can bind to ALK-2, 
which activates the SMAD1 and SMAD5 transport 
proteins. SMAD1 carries the signal for initiating 
the formation and differentiation of fibroblasts. 
BMP-7 is known to have an affinity with ActRI, 
which may suggest that BMP-7 plays a  role in 
these processes [36]. It is also noted that the ab-
sence of BMP-7 is associated with the preferential 
activation of the TGF-b receptor, the phospho-
rylation and activation of SMAD2 and SMAD3, 
followed by their translocation to the nucleus to 
begin the translation of TGF-b products [37]. 
BMP-7 plays a role in the differentiation of 
stem cells into osteoblasts and induction of osteo-
genesis [38], as well as in fibrogenesis and the dif-
ferentiation of myofibroblasts [39]. It is important 
to note that BMP-7 has the potential to partially 
reverse fibrogenesis induced by TGF-b1 in the 
kidneys, heart and colon [40, 41]. In addition, it is 
able to inhibit epithelium-to-mesenchymal tran-
sition (EMT), whose constant activation induces 
chronic inflammation and fibrosis of tissues and 
organs [42]. Mesenchymal tissues, fibroblasts and 
myofibroblasts are the primary cells producing 
the ECM during fibrogenesis. At this stage, BMP-7 
is able to inhibit collagen type I (COL1A2) pro-
duction induced by TGF-b1. BMP-7 inhibits the 
expression of collagen type I mRNA, A-Smooth 
Muscle Actin (A-SMA) and Tissue Inhibitor of 
Metalloproteinase Protein-2 (TIMP) by the induc-
tion of Id2 (Inhibitor of Differentiation 2). BMP-7 
and Id2 reduce the secretion of collagen depen-
dent on TGF-b1 [43]. Transforming growth factor 
(TGF. Collagen types I and III, produced by the 
action of TGF-b1, are the main components of the 
ECM involved in airway remodelling alongside 
laminins, elastins and fibronectins [44]. Therefore 
BMP-7 acts against remodelling by reducing the 
secretion of collagen. 
For another antifibrotic mechanism, it is 
possible to look at the inhibition of the release of 
MMP-2 and MMP-13 metalloproteinases induced 
by TGF-b1 [16]. MMP-13 is one of the main colla-
genases responsible for the degradation of colla-
gen, while MMP-2 hydrolyses the peptide bonds 
in collagen types I, II and III [45]. In asthma, 
metalloproteinases are involved in angiogenesis, 
and hyperplasia of the smooth muscle cells of the 
bronchus resulting from activation by TGF-b1; 
they also have an influence on inflammatory cell 
release and maintaining bronchial hyperrespon-
siveness [46]. Studies have demonstrated a con-
stitutive lowering of BMP-7 levels in human mild 
asthma patients. After exposure to an allergen, 
a significant increase of protein expression was 
observed in the epithelium and in inflammatory 
cells [47]. This confirms that BMP-7 plays a role 
in EMT, but also suggests that it acts as a regulator 
in inflammation and tissue repair [48]. 
A similar increase of TGF-b1 expression was 
observed in both acute and chronic conditions 
in tests on mice immunised with ovoalbumin; 
however, only the chronic group demonstrated 
a fast increase of BMP-7 expression, which cor-
related positively with higher levels of collagen 
deposition. The mice were then subjected to 
specific BMP-7 therapy, which was found to be 
effective at inhibiting collagen type I  induced 
by TGF-b1 [49]. The mouse studies offer promise 
for trials on the use of BMP proteins as markers 
of severe asthma associated with remodelling 
in humans.
The possibilities of clinical use of anti-fibro-
tic mechanism of BMP would be advantageous 
in patients with moderate and severe asthma. 
In patients with less advanced forms of asthma, 
the recombinant BMP proteins would be used 
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Figure 2. Potential regenerative and anti-fibrosis mechanism of BMP-7 based on [43], own modified template. BMP-7 inhibits the expression of collagen type 
I mRNA, A-Smooth Muscle Actin (A-SMA) and Tissue Inhibitor of Metalloproteinase Protein-2 (TIMP) by the induction of Id2. BMP-7 and Id2 reduce the 
secretion of collagen dependent on TGF-b1. The inhibition of fibrosis by reducing collagen secretion and the release of matrix metalloproteinases as well as by 
the inhibition of epithelial-to-mesenchymal transition results in a decrease in intensity of inflammation in the tissues and partial reversion of fibrosis effects
as the causal treatment to prevent fibrosis and 
irreversible rebuilding. We believe that the pre-
vention of the remodelling would keep the dis-
ease under control (evaluated by ACQ- asthma 
control questionnaire), prolong the patient’s life 
and improve its quality (AQLQ- asthma quality 
of life questionnaire). The inhibition of fibrosis 
by reducing collagen secretion and the release 
of matrix metalloproteinases, as well as by the 
inhibition of epithelial-to-mesenchymal transition 
results in a decrease in intensity of inflammation 
in the tissues and partial reversion of fibrosis 
effects. Partial rebuilding of the tissues would be 
clinically manifested by lessening the obstruc-
tion, improving the spirometry results and better 
response to treatment. One of the reasons for 
the ineffectiveness of bronchodilators in severe 
asthma is irreversible obstruction. The use of the 
causal treatment of specific biological therapy and 
recombinant factor inhibiting inflammation and 
fibrosis in combination with conventional anti-in-
flammatory and bronchodilator therapy would 
probably improve the control over the disease and 
prevent its distant effects. For this reason, further 
study of bone morphogenetic proteins, especial-
ly BMP-4 and BMP-7 in terms of their ability to 
inhibit or reverse fibrosis appears to be justified.
It is important to note that in 2001, the FDA 
(Food and Drug Administration) opened clinical 
trials of the osteoinductive potential for recom-
bined rh-BMP7 (Eptotermin-A), which actively 
recruits mesenchymal stem cells from the tissue 
surrounding the bones and initiates a cascade 
of bone formation [50]. Although rhBMP-7 has 
only been used to a  limited degree, this result 
offers hope that other molecules of recombinant 
BMP-7 could be used in the prevention, control 
and treatment of the symptoms of severe asthma 
associated with remodelling. 
Either overexpression or the lack of ex-
pression of any BMPR receptors results in dis-
turbances in intracellular signalling along the 
BMPR-SMAD pathways. In illnesses with im-
paired BMPR-SMAD transduction like Primary 
Pulmonary Hypertension (PPH) or Non-Small 
Cell Lung Cancer (NSCLC), the lack of BMP-regu-
lated signalling promotes the expression of other 
growth factors [51]. Patients with a mild course 
of asthma demonstrate lower constitutive ex-
pression of BMPR-I, BMPR-II, ALK-2 and ALK-6 
receptors, compared to a  control group. This 
suggests that the ‘down-regulation’ of signalling 
pathways in patients with mild disease may con-
tribute to an increase in the activity of remodel-
ling processes after the transition to symptomatic 
asthma. Following exposure to allergen, patients 
with mild asthma demonstrated restitution of 
the BMPR receptors and fast activation of the 
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ligand-activated signalling pathway, which was 
maintained for the following seven days; this 
may be associated with the initiation of the 
cascade of anti-inflammatory and antifibrotic 
processes [47]. 
Summary
Studies have indicated the role played by 
subtypes of bone morphogenetic protein (BMP) 
in the pathogenesis of respiratory diseases accom-
panied by fibrosis. BMP signalling pathways are 
active in the respiratory tract and form an integral 
part of the physiological response to damage to 
the tissue and smooth muscle of the respiratory 
tract. The sources given in this study highlight the 
role of BMP-4 and BMP-7 in the degradation and 
remodelling of the extracellular matrix, which is 
one of the elements involved in the reconstruction 
of the structure of the bronchi in severe forms of 
asthma. The BMP-4 and BMP-7 subtypes exhibit 
antifibrotic effects which act antagonistically to 
TGF-b1, the main cytokine increasing the risk of 
fibrogenesis. 
The effects of BMP are numerous and var-
ied: they modulate the activity of lung fibro-
blasts, myofibroblasts and elements of the 
extracellular matrix. Study results which have 
been obtained so far encourage to conduct in 
vivo and in vitro experiments with the use of 
animal models. Bronchial asthma has been 
found to be associated with dysregulation of 
BMP protein and BMPR receptor expression, 
and the constitutive level of these receptors and 
the changes in their expression may be used 
in diagnostics as predictive markers of severe 
asthma. In addition, disorders at this level can 
be targets for the creation of new small mo lecule 
ligands of the BMPR receptor with the use of 
molecular biology techniques. The antifibrotic 
activities of BMP represent a promising field for 
therapeutic intervention. The possibility of even 
a partial reversal of the effects of airway remo-
delling can significantly translate into control of 
asthma symptoms, reducing the chronic effects 
of the prolonged disease process, extending life 
expectancy and improving the quality of life. 
Further detailed studies of the expression and 
regulation of BMP proteins, their mechanisms 
of activation and intracellular signalling seem to 
be significant from the point of view of diagnos-
tics, reflecting the development of the fields of 
biology and molecular biology, and the growth 
of gene therapy.
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